Is Inmune Bio, Inc. (INMB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.1% / 30% | 59.2% / 30% | 4.0% / 30% | 3950.0% / 5% | ✗ NOT HALAL |
| DJIM | 1.1% / 33% | 59.2% / 33% | 4.0% / 33% | 3950.0% / 5% | ✗ NOT HALAL |
| MSCI | 1.0% / 33% | 52.9% / 33% | 3.6% / 33% | 3950.0% / 5% | ✗ NOT HALAL |
| S&P | 1.1% / 33% | 59.2% / 33% | 4.0% / 33% | 3950.0% / 5% | ✗ NOT HALAL |
| FTSE | 1.0% / 33% | 52.9% / 33% | 3.6% / 50% | 3950.0% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -69724.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -155.8% | |
| Return on Assets (ROA) | -50.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$33M |
| Free Cash Flow | -$33M |
| Total Debt | $384,000 |
| Debt-to-Equity | 4.3 |
| Current Ratio | 4.2 |
| Total Assets | $40M |
Price & Trading
| Last Close | $1.20 |
| 50-Day MA | $1.42 |
| 200-Day MA | $2.16 |
| Avg Volume | 441K |
| Beta | 0.9 |
|
52-Week Range
$1.12
| |
About Inmune Bio, Inc. (INMB)
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Inmune Bio, Inc. (INMB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Inmune Bio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Inmune Bio, Inc.'s debt ratio?
Inmune Bio, Inc.'s debt ratio is 1.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.0%.
What are Inmune Bio, Inc.'s key financial metrics?
Inmune Bio, Inc. has a market capitalization of $30M, and revenue of $14,000. Return on equity stands at -155.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.